Notably, an unbiased framework on investigating the role of several mutations in predicting HMA resistance in MDS showed that EZH2 mutation predicted a lower response, while IDH1 mutation was linked to a higher response rate; seven different mutation combinations including ASXL1, NF1, EZH2, TET2, RUNX1, SRSF2 and BCOR predicted the resistance to HMAs (38, 39). Here, TET2 is linked to myelodysplastic syndrome.